Inclusive oncological trials and targeted treatments cannot ignore sex and gender
Heinrich K, Oertelt-Prigione S (2023)
BMJ Oncology 2(1): e000051.
Zeitschriftenaufsatz
| E-Veröff. vor dem Druck | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Heinrich, Kathrin;
Oertelt-Prigione, SabineUniBi 
Erscheinungsjahr
2023
Zeitschriftentitel
BMJ Oncology
Band
2
Ausgabe
1
Art.-Nr.
e000051
eISSN
2752-7948
Page URI
https://pub.uni-bielefeld.de/record/2980069
Zitieren
Heinrich K, Oertelt-Prigione S. Inclusive oncological trials and targeted treatments cannot ignore sex and gender. BMJ Oncology. 2023;2(1): e000051.
Heinrich, K., & Oertelt-Prigione, S. (2023). Inclusive oncological trials and targeted treatments cannot ignore sex and gender. BMJ Oncology, 2(1), e000051. https://doi.org/10.1136/bmjonc-2023-000051
Heinrich, Kathrin, and Oertelt-Prigione, Sabine. 2023. “Inclusive oncological trials and targeted treatments cannot ignore sex and gender”. BMJ Oncology 2 (1): e000051.
Heinrich, K., and Oertelt-Prigione, S. (2023). Inclusive oncological trials and targeted treatments cannot ignore sex and gender. BMJ Oncology 2:e000051.
Heinrich, K., & Oertelt-Prigione, S., 2023. Inclusive oncological trials and targeted treatments cannot ignore sex and gender. BMJ Oncology, 2(1): e000051.
K. Heinrich and S. Oertelt-Prigione, “Inclusive oncological trials and targeted treatments cannot ignore sex and gender”, BMJ Oncology, vol. 2, 2023, : e000051.
Heinrich, K., Oertelt-Prigione, S.: Inclusive oncological trials and targeted treatments cannot ignore sex and gender. BMJ Oncology. 2, : e000051 (2023).
Heinrich, Kathrin, and Oertelt-Prigione, Sabine. “Inclusive oncological trials and targeted treatments cannot ignore sex and gender”. BMJ Oncology 2.1 (2023): e000051.
Link(s) zu Volltext(en)
Access Level
Open Access
Google Scholar